Table 4 Drugs Commonly Tested Using LTT
| Â | Europe, n (%) | Asia Pacific, n (%) | North America, n (%) | Latin America, n (%) | Africa Middle East, n (%) | Region Not Specified, n (%) | Total (n = 36), n (%) |
|---|---|---|---|---|---|---|---|
Antibiotics (beta-lactams) | 19 (52.8) | 3 (8.3) | 3 (8.3) | 1 (2.8) | 1 (2.8) | 1 (2.8) | 28 (77.8) |
Antibiotics (Non beta-lactams) | 14 (38.9) | 2 (5.6) | 3 (8.3) | 1 (2.8) | 1 (2.8) | 0 (0.0) | 21 (58.3) |
NSAIDs and Selective Cox-2 inhibitors | 11 (30.6) | 1 (2.8) | 1 (2.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 13 (36.1) |
Anti-epileptics | 11 (30.6) | 0 (0.0) | 1 (2.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 12 (33.3) |
Anti-tuberculous drugs | 8 (22.2) | 1 (2.8) | 0 (0.0) | 1 (2.8) | 1 (2.8) | 0 (0.0) | 11 (30.6) |
Pyrazolones | 8 (22.2) | 1 (2.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (5.6) | 11 (30.6) |
Local anesthetic agents | 8 (22.2) | 1 (2.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.8) | 10 (27.8) |
Neuromuscular blockers | 6 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (5.6) | 8 (22.2) |